DOCSLIB.ORG

Comprehensive List of Pharmaceuticals-Related Projects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comprehensive List of Pharmaceuticals-Related Projects Pharmaceutical and R&D Facilities Facility Type Photo Client Location Completion Scope Wakayama/ Solid Dosage TAMURA PHARMACEUTICAL CO.,LTD. 2019 EPCV Japan Gunma/ Bio Bulk DAIICHI SANKYO CHEMICAL PHARMA CO., LTD. 2019 EPCV Japan Hyogo/ R&D Center KANAE CO.,LTD. 2019 EPC Japan API undisclosed Tohoku/Japan 2017 EPCV R&D Center JSR Corporation Tokyo/Japan 2017 EPCV API undisclosed Kitakanto/Japan 2017 EPCV Yamaguchi/ R&D Center TEIJIN PHARMA LIMITED 2015 EPCV Japan Medical Device Menicon Co., Ltd. Chubu/Japan 2014 EPCV Fukushima/ R&D Center SANWA KAGAKU KENKYUSHO CO., LTD. 2014 EPCV Japan Yamaguchi/ Medical Device Terumo Yamaguchi Corporation 2014 E+ES Japan TOYAMA CHEMICAL CO., LTD. Toyama/ Parenteral 2013 EPCV (Current name:FUJIFILM Toyama Chemical Co., Ltd.) Japan Astellas Pharma Inc. Aichi/ Bio Bulk 2013 EPCV (Current name:Micro Biopharm Japan Co.,Ltd.) Japan Kanagawa/ R&D Center Mitsubishi Tanabe Pharma Corporation 2011 EPC Japan Hiroshima/ R&D Center YASUHARA CHEMICAL CO., LTD. 2010 EPC Japan Fukushima/ API TOA EIYO LTD. 2009 EPCV Japan Gunma/ R&D Center SANDEN HOLDINGS CORPORATION 2008 EPC Japan Hyogo/ Packaging KANAE CO., LTD. 2008 EPCV Japan ASAHI GLASS CO., LTD. Chiba/ Bio Bulk 2008 EPCV (Current name:AGC Inc.) Japan 1 / 3 Iwate/ Aseptic API Shionogi & Co., Ltd. 2007 EPCV Japan Mie/ Solid Dosage Sumitomo Dainippon Pharma Co., Ltd. 2007 EPCV Japan Saitama/ Nutrition/Liquid Taisho Pharmaceutical Co., Ltd. 2007 EPCV Japan Kaketsuken Kumamoto/ Vaccine (The Chemo-sero-therapeutic Research Institute) 2006 EPCV Japan (Current name:KM Biologics Co., Ltd.) Niigata/ Vaccine Denka Seiken Co., Ltd. 2006 EPCV Japan Shizuoka/ Bio Bulk Yamaha Motor Co., Ltd. 2006 EPC Japan Daiichi Asubio Pharma Co.,Ltd. Gunma/ Bio Bulk 2005 EPCV （Current name: DAIICHI SANKYO CHEMICAL PHARMA CO., LTD.） Japan Kaketsuken Kumamoto/ Vaccine (The Chemo-sero-therapeutic Research Institute) 2005 EPCV Japan (Current name:KM Biologics Co., Ltd.) Shizuoka/ Parenteral ONO PHARMACEUTICAL CO., LTD. 2004 EPCV Japan Mochida Pharmaceutical Co., Ltd. Tochigi/ Parenteral 2004 EPCV (Current name: Mochida Pharmaceutical Plant Co., Ltd.) Japan PBI Shiga/ Bio Bulk 2004 EPCV (Current name: TOYOBO CO., LTD.) Japan Hyogo/ Regenerative Medicine Kobe Urban Promotion Service Co., Ltd. 2004 EPCV Japan Aichi/ Regenerative Medicine Japan Tissue Engineering Co., Ltd. 2004 EPCV Japan Chinese Traditional Medicine SHANGHAI TSUMURA PHARMACEUTICALS Co., Ltd. China 2003 EPC (Bulk/Solid Dosage) Nara/ R&D Center Santen Pharmaceutical Co., Ltd. 2003 EPC Japan Sumitomo Pharmaceuticals Co., Ltd. Oita/ Parenteral 2003 EPCV (Current name: Sumitomo Dainippon Pharma Co., Ltd.) Japan API GSK Singapore Singapore 2002 EPC Teikoku Hormone MFG. Co., Ltd. Fukushima/ API 2002 EPCV (Current name: ASKA Pharmaceutical. Co., Ltd.) Japan Hyogo/ Regenerative Medicine Kobe Urban Promotion Service Co., Ltd. 2002 EPCV Japan 2 / 3 Shiga/ Parenteral Santen Pharmaceutical Co., Ltd. 2001 EPCV Japan R&D Center UNILEVER Research Colworth Labo England 2000 EPC Solid Dosage SAJAPHCO Saudi Arabia 1999 EPCV Medical Device/ Miyazaki/ Boston Scientific Japan K.K. 1998 EPCV Laboratory/Training Center Japan Hyogo/ Parenteral Eli Lilly Japan K.K. 1998 EPCV Japan Solid Dosage/Parenteral Roche (China) Ltd. China 1997 EPC 3 / 3 .
Load more

Recommended publications
  • Research Paper Inter-Industry Innovations in Terms of Electric Mobility: Should Firms Take a Look Outside Their Industry?
    Inter-industry innovations in terms of electric mobility: Should firms take a look outside their industry? Research Paper Inter-industry innovations in terms of electric mobility: Should firms take a look outside their industry? Stephan von Delft* * University of Münster, Institute of Business Administration at the Department of Chemistry and Pharmacy, Leonardo-Campus 1, 48149 Münster, Germany, [email protected] The beginning electrification of the automotive powertrain is supposed to have a major impact on the automobile value chain - reshaping it significantly and brin- ging up new alliances, business models and knowledge bases. Such a transforma- tion of the value chain might fade boundaries between hitherto distinct knowled- ge bases, technologies, or industries. Over the past decades, the blurring of indus- try boundaries – the phenomenon of industry convergence – has gained attenti- on from researchers and practitioners. The anticipation of a convergence process plays an important role for strategic and innovation management decisions, e.g. for new business development, mergers and acquisitions or strategic partnerships. However, despite the relevance of convergence, it is often challenging for incum- bent firms to (1) foresee such a transformation of their environment, and (2) res- pond strategically to it. Hence, this study presents a tool to anticipate convergen- ce and strategic implications are discussed. 1 Introduction stitute rules of conducting business” (Hacklin et al., 2009, p. 723). Firms facing such a situation, thus Technological change is known as a key driver have to adapt to new knowledge bases and new of economic growth and prosperity (Schumpeter, technologies which do not belong to their former 1947; Abernathy and Utterback, 1978; Kondratieff, core competences or their traditional expertise 1979).
    [Show full text]
  • Nilotinib in Patients with Chronic Myeloid Leukemia: STAT2 Trial in Japan
    Haematologica HAEMATOL/2018/194894 Version 3 Haematologica HAEMATOL/2018/194894 Version 3 Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan Naoto Takahashi, Kaichi Nishiwaki, Chiaki Nakaseko, Nobuyuki Aotsuka, Koji Sano, Chikako Ohwada, Jun Kuroki, Hideo Kimura, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Saori Takahashi, Yoshihiro Kameoka, Hiroyoshi Nishikawa, and Hisashi Wakita Disclosures: 1. This study was supported by research funding from Novartis Pharmaceuticals to N.T. 2. N.T reports grants from Novartis Pharmaceuticals, during the conduct of the study; grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Otsuka, grants and personal fees from Pfizer, personal fees from Bristol-Myers Squibb, outside the submitted work; K.N reports grants from Zenyaku Kogyo Company, Limited, grants from Chugai Pharmaceutical, grants from Novartis Pharma K.K., grants from Kyowa Hakko Kirin Co, Ltd, grants from Nippon Shinyaku Co, Ltd, outside the submitted work; C.N reports personal fees from Novartis, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Pfizer, grants and personal fees from Takeda pharmaceuticals, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Otsuka Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Asahi Kasei Pharma, grants and personal fees from Shionogi, personal fees from Shire, personal fees from Jannsen, personal fees from Celgene, outside the submitted work; M.T. reports personal fees from Bristol-Myers Squib, personal fees from Pfizer, outside the submitted work; K.M reports grants from Kyowa Hakko Kirin Co.
    [Show full text]
  • 1332 Nippon Suisan Kaisha, Ltd. 50 1333 Maruha Nichiro Corp. 500 1605 Inpex Corp
    Nikkei Stock Average - Par Value (Update:August/1, 2017) Code Company Name Par Value(Yen) 1332 Nippon Suisan Kaisha, Ltd. 50 1333 Maruha Nichiro Corp. 500 1605 Inpex Corp. 125 1721 Comsys Holdings Corp. 50 1801 Taisei Corp. 50 1802 Obayashi Corp. 50 1803 Shimizu Corp. 50 1808 Haseko Corp. 250 1812 Kajima Corp. 50 1925 Daiwa House Industry Co., Ltd. 50 1928 Sekisui House, Ltd. 50 1963 JGC Corp. 50 2002 Nisshin Seifun Group Inc. 50 2269 Meiji Holdings Co., Ltd. 250 2282 Nh Foods Ltd. 50 2432 DeNA Co., Ltd. 500/3 2501 Sapporo Holdings Ltd. 250 2502 Asahi Group Holdings, Ltd. 50 2503 Kirin Holdings Co., Ltd. 50 2531 Takara Holdings Inc. 50 2768 Sojitz Corp. 500 2801 Kikkoman Corp. 50 2802 Ajinomoto Co., Inc. 50 2871 Nichirei Corp. 100 2914 Japan Tobacco Inc. 50 3086 J.Front Retailing Co., Ltd. 100 3099 Isetan Mitsukoshi Holdings Ltd. 50 3101 Toyobo Co., Ltd. 50 3103 Unitika Ltd. 50 3105 Nisshinbo Holdings Inc. 50 3289 Tokyu Fudosan Holdings Corp. 50 3382 Seven & i Holdings Co., Ltd. 50 3401 Teijin Ltd. 250 3402 Toray Industries, Inc. 50 3405 Kuraray Co., Ltd. 50 3407 Asahi Kasei Corp. 50 3436 SUMCO Corp. 500 3861 Oji Holdings Corp. 50 3863 Nippon Paper Industries Co., Ltd. 500 3865 Hokuetsu Kishu Paper Co., Ltd. 50 4004 Showa Denko K.K. 500 4005 Sumitomo Chemical Co., Ltd. 50 4021 Nissan Chemical Industries, Ltd. 50 4042 Tosoh Corp. 50 4043 Tokuyama Corp. 50 WF-101-E-20170803 Copyright © Nikkei Inc. All rights reserved. 1/5 Nikkei Stock Average - Par Value (Update:August/1, 2017) Code Company Name Par Value(Yen) 4061 Denka Co., Ltd.
    [Show full text]
  • Kuraray/ Glsv Business
    EN Case No COMP/M.7115 - KURARAY/ GLSV BUSINESS Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) in conjunction with Art 6(2) Date: 29/04/2014 In electronic form on the EUR-Lex website under document number 32014M7115 Office for Publications of the European Union L-2985 Luxembourg EUROPEAN COMMISSION Brussels, 29.4.2014 C(2014) 2946 final In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 PUBLIC VERSION concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a MERGER PROCEDURE general description. To the notifying party: Dear Sir/Madam, Subject: Case M.7115 – Kuraray/ GLSV Business Commission decision pursuant to Article 6(1)(b) in conjunction with Article 6(2) of Council Regulation No 139/20041 1. On 6 March 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ("the Merger Regulation") by which Kuraray Co., Ltd. ("Kuraray", Japan) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control over the Glass Laminating Solutions/Vinyls Business ("GLSV") of E. I. du Pont de Nemours and Company ("DuPont", USA), by way of purchase of assets. Kuraray and GLSV are hereinafter collectively referred to as "the Parties" while Kuraray individually is referred to as "Notifying Party". I. THE PARTIES AND THE OPERATION 2.
    [Show full text]
  • Anellotech Plas-Tcat Funding from R Plus Japan Press Release June 30
    Anellotech Secures Funds to Develop Innovative Plas-TCatTM Plastics Recycling Technology from R Plus Japan, a New Joint Venture Company launched by 12 Cross-Industry Partners within the Japanese Plastic Supply Chain Pearl River, NY, USA, (June 30, 2020) —Sustainable technology company Anellotech has announced that R Plus Japan Ltd., a new joint venture company, will invest in the development of Anellotech’s cutting-edge Plas-TCatTM technology for recycling used plastics. R Plus Japan was established by 12 cross-industry partners within the Japanese plastics supply chain. Member partners include Suntory MONOZUKURI Expert Ltd. (SME, a subsidiary of Suntory Holdings Ltd.), TOYOBO Co. Ltd., Rengo Co. Ltd., Toyo Seikan Group Holdings Ltd., J&T Recycling Corporation, Asahi Group Holdings Ltd., Iwatani Corporation, Dai Nippon Printing Co. Ltd., Toppan Printing Co. Ltd., Fuji Seal International Inc., Hokkaican Co. Ltd., Yoshino Kogyosho Co. Ltd.. Many plastic packaging materials are unable to be recycled and are instead thrown away after a single use, often landfilled, incinerated, or littered, polluting land and oceans. Unlike the existing multi-step processes which first liquefy plastic waste back into low value “synthetic oil” intermediate products, Anellotech’s Plas- TCat chemical recycling technology uses a one-step thermal-catalytic process to convert single-use plastics directly into basic chemicals such as benzene, toluene, xylenes (BTX), ethylene, and propylene, which can then be used to make new plastics. The technology’s process efficiency has the potential to significantly reduce CO2 emissions and energy consumption. Once utilized across the industry, this technology will be able to more efficiently recycle single-use plastic, one of the world’s most urgent challenges.
    [Show full text]
  • Factset-Top Ten-0521.Xlsm
    Pax International Sustainable Economy Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight ASML Holding NV 34,391,879.94 4.3 Roche Holding Ltd 28,162,840.25 3.5 Novo Nordisk A/S Class B 17,719,993.74 2.2 SAP SE 17,154,858.23 2.1 AstraZeneca PLC 15,759,939.73 2.0 Unilever PLC 13,234,315.16 1.7 Commonwealth Bank of Australia 13,046,820.57 1.6 L'Oreal SA 10,415,009.32 1.3 Schneider Electric SE 10,269,506.68 1.3 GlaxoSmithKline plc 9,942,271.59 1.2 Allianz SE 9,890,811.85 1.2 Hong Kong Exchanges & Clearing Ltd. 9,477,680.83 1.2 Lonza Group AG 9,369,993.95 1.2 RELX PLC 9,269,729.12 1.2 BNP Paribas SA Class A 8,824,299.39 1.1 Takeda Pharmaceutical Co. Ltd. 8,557,780.88 1.1 Air Liquide SA 8,445,618.28 1.1 KDDI Corporation 7,560,223.63 0.9 Recruit Holdings Co., Ltd. 7,424,282.72 0.9 HOYA CORPORATION 7,295,471.27 0.9 ABB Ltd. 7,293,350.84 0.9 BASF SE 7,257,816.71 0.9 Tokyo Electron Ltd. 7,049,583.59 0.9 Munich Reinsurance Company 7,019,776.96 0.9 ASSA ABLOY AB Class B 6,982,707.69 0.9 Vestas Wind Systems A/S 6,965,518.08 0.9 Merck KGaA 6,868,081.50 0.9 Iberdrola SA 6,581,084.07 0.8 Compagnie Generale des Etablissements Michelin SCA 6,555,056.14 0.8 Straumann Holding AG 6,480,282.66 0.8 Atlas Copco AB Class B 6,194,910.19 0.8 Deutsche Boerse AG 6,186,305.10 0.8 UPM-Kymmene Oyj 5,956,283.07 0.7 Deutsche Post AG 5,851,177.11 0.7 Enel SpA 5,808,234.13 0.7 AXA SA 5,790,969.55 0.7 Nintendo Co., Ltd.
    [Show full text]
  • Daiichi Sankyo Company, Limited
    [Translation] CONVOCATION NOTICE OF THE 14TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Year Ended March 31, 2019 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts etc. originally issued in the Japanese version. - 1 - [Translation] To Our Shareholders At the Daiichi Sankyo Group (“the Group”), we are proceeding with the initiatives of 4th mid- term business plan with the aim of becoming a “Global Pharma Innovator with Competitive Advantage in Oncology” as set forth in our 2025 Vision. In fiscal 2018, we made significant progress in developing new drugs in oncology area, including DS-8201, an antibody drug conjugates utilizing our proprietary technologies. In addition, we entered into a strategic collaboration agreement with AstraZeneca, which has strengths in the oncology business, for the global development and commercialization of DS-8201 in order to maximize its value. Furthermore, sales of mainstay products such as edoxaban, an anticoagulant which supports current earnings of the Group, were firm in Japan and overseas. The achievement of initial target of mid-term business plan for fiscal 2020 is expected to be delayed by two years due to failure of achievement of the plan for pain franchise business and additional investments in research and development. However, we are gaining confidence of achieving our 2025 Vision and accelerating growth in the future due to the significant improvement in the value of oncology area pipelines. We will continue to make every effort to achieve the goals of the Medium-Term Management Plan and 2025 Vision. I greatly appreciate your continued support in the future.
    [Show full text]
  • Daiichi Sankyo Group Value Report 2019
    External Evaluations (as of June 30,2019) ™ Daiichi Sankyo Group Value Report 2019 Value Daiichi Sankyo Group MSCI Japan Empowering Women Select Index THE INCLUSION OF DAIICHI SANKYO CO.,LTD. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF DAIICHI SANKYO CO.,LTD. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADE- MARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES. “Eruboshi” Certification Mark “Kurumin” Certification Mark Logo given to Certified Health and Productivity Management Organization (White500) This report uses FSC® certified paper, which indicates that the paper used to print this Paper report was produced from properly managed forests. 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan This report was printed using 100% Inks biodegradable printing inks from vegetable Corporate Communications Department oil. Daiichi Sankyo Group Tel: +81-3-6225-1126 CSR Department The waterless printing method used for this Value Report 2019 Tel: +81-3-6225-1067 Printing report minimized the use and release of harmful liquid wastes. https://www.daiichisankyo.com/ Printed in Japan 005_7045687911909.indd 1 2019/09/27 18:22:19 Introduction Our Mission The Core Values and Commitments serve as the criteria for business activities and In addition, we have established the DAIICHI SANKYO Group Corporate Conduct Charter . decision-making used by executive officers and employees in working to fulfill Our Mission . This charter calls on us to fulfill our social responsibilities by acting with the highest ethical Our Corporate Slogan succinctly explains the spirit of Our Mission, Core Values and standards and a good social conscience appropriate for a company engaged in business Commitments.
    [Show full text]
  • Sumitomo Chemical 100 Years Sumitomo Chemical 100 Years Published: August 2014 Published by Sumitomo Chemical Co.,Ltd
    Sumitomo Chemical 100 Years Sumitomo Chemical 100 Years Published: August 2014 Published by Sumitomo Chemical Co.,Ltd. Production and editing : Sumitomo Chemical Co.,Ltd., Corporate History Editorial Office 27-1, Shinkawa 2-chome, Chuo-ku, Tokyo, Japan Production assisted by Dai Nippon Printing Co.,Ltd. Printed in Japan by Dai Nippon Printing Co.,Ltd. CONTENTS Chairman’s Message President’s Message The Path to a Global Chemical Company 1. The History of Sumitomo 8 2. History of Sumitomo Fertilizer Works 10 3. Going from a Fertilizer Manufacturer to a Chemical Company 14 4. Moving into Fine Chemicals 16 5. Post-war Recovery 18 6. Moving into the Agricultural Chemicals Business 20 7. Growth of the Pharmaceuticals Sector 22 8. Entering the Field of Petrochemicals 24 9. Dealing with the Oil Crises 26 10. Rise and Decline of Aluminum Business 28 11. Construction of Singapore Petrochemical Complex 32 12. Separation of Pharmaceutical Business from Sumitomo Chemical and Inauguration 34 of Dainippon Sumitomo Pharma Co., Ltd. 13. Expansion of Agricultural Chemicals Business 36 14. IT-related Chemicals Sector Established and Business Grows 38 15. Progress of the Rabigh Project 40 16. Aiming to be a Truly Global Chemical Company 42 17. For a Better Tomorrow 46 Reports from Regional Headquarters 48 Report from Beijing by Sumitomo Chemical (China) Co., Ltd. 48 Report from Singapore by Sumitomo Chemical (Asia Pacific) Pte Ltd 50 Report from Brussels by Sumitomo Chemical Europe S.A./N.V. 52 Report from New York by Sumitomo Chemical America, Inc. 54 The Sumitomo Spirit and Sumitomo Chemical’s Business Philosophy 56 Recent Sales and Profits 57 Sumitomo Chemical Locations in Japan 58 Major Companies of Sumitomo Chemical Group: Japan 59 Major Companies of Sumitomo Chemical Group: International 60 Chronology of Sumitomo Chemical 62 Chairman’s Message In October 2015, Sumitomo Chemical will cele- triggered by the fall of Lehman Brothers and the sub- brate its 100 year anniversary.
    [Show full text]
  • Convocation Notice of the 16Th Ordinary General Meeting of Shareholders
    [Translation] CONVOCATION NOTICE OF THE 16TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Year Ended March 31, 2021 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts etc. originally issued in the Japanese version. [Translation] To Our Shareholders We sincerely appreciate the continuous kindness of our shareholders. In addition, we would like to express our deepest sympathies to those who passed away due to COVID-19, and thank the medical personnel who are close to those who are fighting illness and are making efforts in treatment. We will continue to devote ourselves to the research and development of vaccines and therapeutic agents. Our “Purpose” is to “contribute to the enrichment of quality of life around the world.” As a pharmaceutical company with strengths in science and technology, we continuously create innovative pharmaceuticals and provide pharmaceuticals that meet diverse medical needs to provide sustainable value to society. We were able to launch the anti-cancer drug “Enhertu”, which is an antibody-drug conjugate (ADC) that utilizes our unique technology, in Japan and Europe in fiscal 2020, following the launch in the U.S. in fiscal 2019. Subsequent ADCs such as Dato-DXd and HER3-DXd are also steadily developing. Now, we have newly established our 2030 Vision of being an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society,” and have established 5-Year Business Plan (fiscal 2021 to fiscal 2025) as a plan to realize our 2025 Vision, “Global Pharma Innovator with Competitive Advantage in Oncology.” By working together as a Daiichi Sankyo Group on 5-Year Business Plan toward the 2030 Vision, we aim to solve the social issues expected of our company and increase shareholder value.
    [Show full text]
  • Research and Development in Breast Ultrasound E
    E. Ueno, T. Shiina, M. Kubota, K. Sawai (Eds.) Research and Development in Breast Ultrasound E. Ueno, T. Shiina M. Kubota, K. Sawai (Eds.) Research and Development in Breast Ultrasound With 150 Figures, Including 37 in Color 1 3 Ei Ueno, M.D., Ph.D. Associate Professor, Department of Breast-Thyroid-Endocrine Surgery Institute of Clinical Medicine, University of Tsukuba 1-1-1 Tennodai, Tsukuba, Ibaraki 304-8573, Japan Tsuyoshi Shiina, Ph.D. Professor, Institute of Information Sciences and Electronics, University of Tsukuba 1-1-1 Tennodai, Tsukuba, Ibaraki 304-8573, Japan Mitsuhiro Kubota, M.D. Director of Yamachika Memorial Hospital 3-19-14 Koyawata, Odawara, Kanagawa 256-0815, Japan Kiyoshi Sawai, M.D. Associate Professor, Department of Endocrine & Breast Surgery Kyoto Prefectural University of Medicine 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-0841, Japan Cover Illustration: Madoka Momota Library of Congress Control Number: 2004116202 ISBN 4-431-40277-2 Springer-Verlag Tokyo Berlin Heidelberg New York This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broad- casting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and appli- cation thereof contained in this book.
    [Show full text]
  • Daiichi Sankyo Company, Limited
    [Translation] CONVOCATION NOTICE OF THE 6TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Period Ended March 31, 2011 Daiichi Sankyo Company, Limited - 1 - [Translation] (Securities Identification Code 4568) May 31, 2011 To Shareholders, Daiichi Sankyo Company, Limited Joji Nakayama, Representative Director and President & CEO 5-1, Nihonbashi Honcho 3-chome, Chuo-ku, Tokyo, Japan CONVOCATION NOTICE OF THE 6TH ORDINARY GENERAL MEETING OF SHAREHOLDERS We wish to extend our deepest sympathy to all those who have suffered hardship from the Great East Japan Earthquake that occurred in March 2011. Daiichi Sankyo Company, Limited (“the Company”) respectfully requests your attendance at the 6th Ordinary General Meeting of Shareholders (“the Meeting”), which will be held as detailed below. If you will not be able to attend the Meeting, you may exercise your voting rights through either of the methods described below, in which case we ask that you please exercise your voting rights by 17:30 (within our business hours), Friday, June 24, 2011 (Japan Time), after examining the attached reference documents. [Exercise of Voting Rights by Mail] Please indicate your approval or disapproval for the proposals on the enclosed voting form and return the form to the Company. Please note that the form must be received by the Company no later than the above-mentioned deadline. [Exercise of Voting Rights on the Internet etc.] After examining “Information on Exercise of Voting Rights, etc.” on pages 57 and 58, please vote on the Internet at the dedicated voting website (http://www.evote.jp/) no later than the above-mentioned deadline. The Company is participating in the platform for electronic exercise of voting rights for institutional investors operated by ICJ Inc.
    [Show full text]